地衣芽胞杆菌活菌制剂治疗肝病患者肠源性内毒素血症的临床疗效

Clinical Efficacy of Bacillus Licheniformis Biogen in the Treatment of Intestinal Endotoxemia in Patients with Liver Disease

目的探讨地衣芽胞杆菌活菌制剂对肝病患者肠源性内毒素血症的临床治疗作用。方法将45例肝病且具有肠源性内毒素血症的患者分为观察组和对照组,2组间在性别、年龄、病程、临床特点及血清内毒素水平方面差异无统计学意义,观察组在对照组的基础上加用地衣芽胞杆菌活菌制剂治疗,治疗3周后再次检测2组的血清内毒素水平,并进行统计学分析。结果治疗前2组血清内毒素水平分别为(67.15±29.22)和(65.61±28.17)pg/ml。差异无统计学意义(P>0.05)。治疗后2组血清内毒素水平分别为(30.84±15.56)和(56.79±27.01)pg/ml(P<0.05),差异有统计学意义。结论地衣芽胞杆菌活菌制剂对肝病患者肠源性内毒素血症有治疗作用。

[Objective]To discuss the clinical efficacy of bacillus licheniformis biogen in the treatment of intestinal endotoxemia in patients with liver disease.[Methods]38 liver disease patients with intestinal endotoxemia were divided into the observation group and the control group,and there was no significant difference in sex,age,course of disease,clinical characteristics and level of serum endotoxin between two groups.On the basis of control group treatment,the observation group was treated with additional bacillus licheniformis biogen for 3 weeks,and the serum endotoxin level of two groups were tested and statistically analyzed.[Results]Before treatment,the serum endotoxin level of two groups was（67.15±29.22） pg/ml and（65.61±28.17） pg/ml respectively,and there was no significant difference between two groups（P0.05）.After treatment,the serum endotoxin level of two groups was（30.84±15.56） and（56.79±27.01） pg/ml respectively,and the difference was significant（P0.05）.[Conclusion]The bacillus licheniformis biogen has the clinical efficacy on intestinal endotoxemia in patients with liver disease.